Bristol-Myers Squibb (BMY) Tops Q2 EPS by 1c; Raises FY11 Outlook
Tweet
Share
E-mail
Get Alerts BMY Hot Sheet
Price: $63.60 -1.62%
Financial Fact:
Research and development: 1.14B
Today's EPS Names:
SVBT, ZEO, OTLK, More
Financial Fact:
Research and development: 1.14B
Today's EPS Names:
SVBT, ZEO, OTLK, More
Join SI Premium – FREE
Bristol-Myers Squibb Company (NYSE: BMY) reported Q2 EPS of $0.56, $0.01 better than the analyst estimate of $0.55. Revenue for the quarter came in at $5.4 billion versus the consensus estimate of $5.04 billion.
Sees FY2011 EPS of $2.20-$2.30, versus prior guidance of $2.10-$2.20 and the consensus of $2.21.
Sees FY2011 EPS of $2.20-$2.30, versus prior guidance of $2.10-$2.20 and the consensus of $2.21.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
- Atrium Therapeutics receives $15M milestone from Bristol Myers Squibb
- CaliberCos Inc (CWD) Misses Q2 EPS by 43c; Offers Guidance
Create E-mail Alert Related Categories
Earnings, Guidance, Hot EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
